Transplantation (Renal)
8 cases on ureteral stent timing after a tense anastomosis, asymptomatic bacteriuria beyond the early post-transplant window, recurrent UTI from ureteral reimplant reflux, immunosuppression selection in a neurogenic-bladder recipient, tacrolimus-sildenafil interaction asymmetry, mycophenolate washout timing before conception, sirolimus conversion after recurrent skin cancer, and NSAID/thromboprophylaxis decisions in a living kidney donor — choose a case below to open its full multi-voice debate.
A living-donor recipient's ureteral stent is due for its scheduled removal, but a tense anastomosis and an asymptomatic positive culture pull the team in opposite directions on how long the stent should stay — and whether the culture should be treated at all.
An established transplant recipient's routine surveillance culture comes back positive with no symptoms at all, and the reflex to treat a single, irreplaceable kidney runs directly against three separate randomized trials that found nothing to treat.
A transplant recipient's fourth febrile urinary tract infection this year traces back to reflux at the ureteral reimplant site, not to any organism — and the debate is no longer about which drug, but how many more courses of one are worth trying before the answer is a second operation.
A spinal cord injury patient who has self-catheterized for fifteen years is about to receive the kidney his own bladder eventually destroyed, and neither his induction regimen nor his overactive-bladder drug has ever been studied in someone doing both at once.
A young transplant recipient's new erectile dysfunction has a straightforward pharmacologic fix, except that the one interaction study everyone quotes only tells half the story — his drug doesn't move his tacrolimus level, but his tacrolimus moves his drug's.
A young transplant recipient wants to start trying to conceive, and the drug protecting her graft is also the one the FDA built a formal registry around for what it does to a first-trimester pregnancy — leaving the timing of the switch, not the switch itself, as the real argument.
A long-term transplant recipient's fourth skin cancer puts a well-known immunosuppression switch on the table — except the trial behind that switch found its benefit disappear in patients with a history exactly like his.
A healthy woman about to give up a kidney for her brother forces the team to weigh an opioid-sparing painkiller against a guideline caution built on no real evidence at all — in the one surgical patient whose remaining organ has to work perfectly for the rest of her life.